NSCLC metastatic/molecular target

 
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 13/08/2019)

EGFR
Currently no trials

ALK
Currently no trials

KRAS
LXH254-LTT462 (Novartis) -> for 3th line and higher (currently on hold)
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer. 

RET
Currently no trials

BRAF
LXH254-LTT462 (Novartis) -> for 3th line and higher (currently on hold)
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer. 

C-MET
CINC280 (Novartis) -> for 1st line
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer
(only cohort 7 open)

ROS1
BFAST (Roche)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial).
(only cohort D open)
 
New trial in start-up: currently no new trials